throbber
Bonus CD-ROM
`Available!
`See Back Cover
`for More Details
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 1
`
`

`

`--
`
`Editor: David B. Troy
`Managing Editor: Matthew J. Hauber
`Marketing Manager: Marisa A. O'Brien
`
`Lippincott Williams & Wilkins
`
`351 West Camden Street
`Baltimore, Maryland 21201-2436 USA
`
`530 Walnut Street
`Philadelphia, PA 19106
`
`.·
`
`All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means,
`including photocopying, or utilized by any information storage and retrieval system without written permission from the copy(cid:173)
`right owner.
`
`The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury res~lting from any
`material contained herein. This publication contains information relating to general principles of medical care which should not
`be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be
`reviewed for current information, including contraindications, dosages and precautions.
`
`Printed in the United States of America
`
`Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at
`Washington DC
`
`Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington
`
`Copyright 1926, 1936, by the Joseph P Remington Estate
`
`Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science
`
`Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science
`
`Copyright 2000, 2006, by the University of the Sciences in Philadelphia
`
`All Rights Reserved
`Library of Congress Catalog Card Information is available
`ISBN 0-7817-4673-6
`
`The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked
`any, they will be pleased to make the necessary arrangements at the first opportunity.
`
`The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The
`Convention is not responsible for any inaccuracy contained herein.
`
`Notice-This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official
`United States Pharmacopeia (USP) and I or the National Formulary (NF). In the event of any difference or discrepancy between the
`current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them
`herein, the context and effect of the official compendia shall prevail.
`
`To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301)
`824-7390. International customers should call (301) 714-2324.
`
`1 2 3 4 5 6 7 8 9 10
`
`-
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 2
`
`

`

`Contents
`
`Part 1
`
`Orientation
`
`2
`3
`4
`5
`6
`7
`8
`
`9
`10
`
`. .... .3
`. . . . .
`. . . . . . . . .
`. . . .
`Scope of Pharmacy
`Evolution of Pharmacy .. ........ .. ....... . ...... . . 7
`Ethics and Professionalism . . . . . .
`. . . . . . . . . .
`.20
`The Practice of Community Pharmacy . ............... 30
`Pharmacists in Industry . . . . . . . . . . . . . . . . . . . . .
`. ... 35
`Pharmacists in Government . . .
`. ........ . .40
`Pharmacists and Public Health . .
`. ..... . .. . . . . . ... .51
`Information Resources in Pharmacy and the
`Pharmaceutical Sciences
`Clinical Drug Literature
`Research .. . ... . .
`
`. .. 64
`.74
`. . . 87
`
`. '...
`
`Part 2
`
`Pharmaceutics
`
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`
`Metrology and Pharmaceutical Calculations .. . . . .. . . . . 99
`Statistics
`.... ... .. . ........ ........ . . ...... 127
`Molecular Structure, Properties, and States of Matter
`. 162
`Complex Formation
`. . . . . . . .
`. . . . . . . . . . . . . .
`. . 186
`. . . 201
`Thermodynamics . . . . . . . . . . . . . . . . . . . . . . . . . .
`.211
`Solutions and Phase Equilibria ..
`.231
`Ionic Solutions and Electrolytic Equil ibria
`. . 250
`Tonicity, Osmoticity, Osmolality, and Osmolarity
`.266
`Chemical Kinetics .... . . .... . . . . . ... .. .
`.2M
`lnterfacial Phenomena ....
`.293
`Colloidal Dispersions .
`.319
`Coarse Dispersions
`. ..... . ..... 338
`Rheology ....
`
`Part 3
`
`Pharmaceutical Chemist!}'_
`
`24
`25
`26
`27
`28
`29
`
`......... . ..... 361
`Inorganic Pharmaceutical Chemistry
`.3%
`Organic Pharmaceutical Chemistry
`. .410
`Natural Products .... . .
`Drug Nomenclature-United States Adopted Names ... .443
`Structure-Activity Relationship and Drug Design .. . . . . .468
`....... 479
`Fundamentals of Medical Radionuclides
`
`Part 4
`
`Pharmaceutical Testing, Analysis, and Control
`
`30
`31
`32
`33
`34
`35
`
`Analysis of Medicinals .
`Biological Testing
`. .. ..... . . . .
`Clinical Analysis
`. . . . . . . . . .
`Chromatography
`Instrumental Methods of Analysis
`Dissolution ...... . .
`
`.495
`.553
`.565
`.599
`... . ..... 633
`. .......... 672
`
`. . . ...
`
`Part S
`
`Pharmaceutical Manufacturing
`
`36
`37
`38
`39
`40
`41
`42
`43
`44
`45
`46
`47
`48
`
`Separation
`. ~1
`. .............. . . ... ... . ..... 7~
`Powders
`.720
`Property-Based Drug Design and Preformulation
`.MS
`Solutions, Emulsions, Suspensions, and Extracts . . ..
`Sterilization ..... . ..... . . .. . . .
`. 7~
`.M2
`Parenteral Preparations . . . . . . .
`. . ~7
`Intravenous Admixtures ........ . . .
`Ophthalmic Preparations . ....... . . . . . .
`. 8~
`Medicated Topicals . . . ... . .. . . .
`. ~1
`Oral Solid Dosage Forms
`.~9
`Coating of Pharmaceutical Dosage Forms
`.929
`. . ~9
`Extended-Release and Targeted Drug Delivery Systems
`The New Drug Approval Process and
`Clinical Trial Design .... . . . .. . . .. . .
`
`. ..... . .... 965
`
`. . . . ..
`
`49
`50
`51
`52
`53
`54
`55
`
`. .......... 976
`. . . . . . . . . .
`Biotechnology and Drugs
`Aerosols .... ... ............ . . . ... . .. . . . .. . .. 1000
`. .. 1018
`Quality Assurance and Control
`. . . . . . . . . . .
`Stability of Pharmaceutical Products
`. . . . . . . . .
`. ... 1025
`Bioavailability and Bioequivalency Testing .......... . 1037
`Plastic Packaging Materials
`................. . 1047
`Pharmaceutical Necessities
`.. 1058
`
`Part 6
`
`Pharmacokinetics and Pharmacodinamics
`
`56
`57
`58
`59
`60
`61
`62
`63
`
`Diseases: Manifestations and Pathophysiology .... . .. 1095
`Drug Absorption, Action, and Disposition ... ... . ... . 1142
`Basic Pharmacokinetics and Pharmacodynamics ...... 1 171
`Clinical Pharmacokinetics and Pharmacodynamics ... . . 1 191
`Priniciples of Immunology ..................... .. 1206
`... 1221
`Adverse Drug Reactions and Clinical Toxicology
`Pharmacogenomics .............. .
`. . . 1230
`Pharmacokinetics/Pharmacodynamics in
`Drug Development
`
`.. 1249
`
`Part 7
`
`Pharmaceutical and Medicinal Agents
`
`64
`65
`66
`67
`68
`69
`70
`71
`72
`
`73
`74
`75
`76
`77
`78
`79
`80
`81
`82
`83
`84
`85
`86
`87
`88
`89
`90
`91
`92
`93
`
`Diagnostic Drugs and Reagents ................. . . 1261
`.. 1277
`Topical Drugs
`Gastrointestinal and Liver Drugs ....... ... . . ...... 1294
`Blood, Fluids, Electrolytes, and Hematological Drugs .
`. 1318
`Cardiovascular Drugs ........ . . . ... . ........... 1350
`Respiratory Drugs
`............ . ... . ....... 1371
`Sympathomimetic Drugs . . . .
`. ............. . . 1379
`Chol inomimetic Drugs
`. . . . . . . .. 1389
`Adrenergic Antagonists and Adrenergic
`. .. . .... 1399
`Neuron Blocking Drugs .
`. . . . . . . . . . . . .
`Antimuscarinic and Antispasmodic Drugs ..... . ..... 1405
`Skeletal Muscle Relaxants ............... . . . ..... 141 1
`Diuretic Drugs . . . . . . .
`. ......... . ... . ..... . . 1422
`Uterine and Antimigraine Drugs ....... . . . ....... . 1432
`Hormones and Hormone Antagonists . . . . . . . . . .
`. 1437
`General Anesthetics
`. . . . . . .
`. . . . . . . . . . .
`. .. . . 1474
`.. 1479
`Local Anesthetics
`Antianxiety Agents and Hypnotic Drugs .. .. ....... . 1486
`Antiepileptic Drugs ........ . . . ................. 1501
`Psychopharmacologic Agents . . . . . . .
`. ...... 1 509
`Analgesic, Antipyretic, and Anti-Inflammatory Drugs ... 1 524
`...... 1543
`Histamine and Antihistaminic Drugs
`Central Nervous System Stimulants ... . . .... ... . ... 1551
`Antineoplastic Drugs .
`. . . . ........... . ....... . . 1 556
`lmmunoactive Drugs ......... . .. . . ... . . . . . . . ... 1588
`Parasiticides
`. . . . . . . . . . . . . . .
`. . . . . . .
`. . 1 595
`Immunizing Agents and Allergenic Extracts .......... 1600
`Anti-lnfectives . . . . . . . . . .
`. . 1626
`Enzymes . . . . . . . . . . . . . . . . . . .
`. .. . ......... . 1685
`Nutrients and Associated Substances
`.. . ... . ....... 1688
`. '' ' ........... 1719
`Pesticides
`
`Part 8
`
`Pharmac}'_ Practice
`
`A Fundamentals of Pharmacy Practice
`Application of Ethical Principles to Practice Dilemmas .. 1745
`Technology and Automation . . . . ..... . ....... . ... 1753
`The Patient: Behavioral Determinants . . . . . . . ... . ... 1762
`Patient Communication
`. . . .
`. ......... . 1770
`. .. 1782
`Patient Compliance . . . . . . . . . . . . . . . . . . . . .
`Drug Education . . . . . . . . . .
`. . . ... . ...... . ... 1 796
`
`94
`95
`96
`97
`98
`99
`
`xxi
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 3
`
`

`

`xx ii
`
`CONTENTS
`
`100
`101
`102
`
`103
`104
`105
`106
`107
`108
`109
`110
`
`111
`112
`113
`114
`115
`116
`
`.......... 1808
`. ......... 1823
`
`Professional Communications
`The Prescription ........ .
`Providing a Framework for Ensuring
`................ . ..... 1840
`Medication Use Safety
`Poison Control
`.... . ....... . ....... 1881
`. ....... . ............ 1889
`. . . .
`Drug Interactions
`Extemporaneous Prescription Compounding
`.. 1903
`Nuclear Pharmacy Practice
`. . . . . . . .
`. .. 1913
`Nutrition in Pharmacy Practice . . . .
`.1925
`Pharmacoepidemiology .............. . ..... .. ... 1958
`Surgical Supplies . . . . . . . . . . . . . . . . . . . . . .
`. .1968
`Health Accessories
`. . . . . . . . . . . . . . . . . . .
`.1979
`
`B Social, Behavioral, Economic, and
`Administrative Sciences
`....... 2015
`Laws Governing Pharmacy
`. ....... 2055
`Re-engineering Pharmacy Practice .
`. ..... 2070
`Pharmacoeconomics . . . . . . . . . . . . . .
`Community Pharmacy Economics and Management ... 2082
`Product Recalls and Withdrawals .................. 2098
`Marketing Pharmaceutical Care Services
`.... . ... 2107
`
`117
`
`118
`119
`
`120
`121
`122
`
`123
`124
`125
`126
`127
`128
`129
`130
`131
`132
`133
`
`Documenting, Billing, and Reimbursement for
`Pharmaceutical Care Services
`. .... .
`Pharmaceutical Risk Management . .
`Integrated Health Care Delivery Systems
`
`. .2114
`.. 2124
`......... 2130
`
`..... 2155
`.2163
`
`C Patient Care
`Specialization in Pharmacy Practice
`Pharmacists and Disease State Management
`Development of a Pharmacy Care Plan and
`.2170
`Patient Problem-Solving
`. . . . . . . . . . . . .
`. .2179
`Ambulatory Patient Care . . . . . . . . . . . . . . . . .
`Self-Care . . . .
`. .......... . ....... 2197
`Diagnostic Self-Care . . . .
`. ... . . .. . .. ........ 2206
`Preventive Care . . .
`. . . . . . . . . . .
`.2223
`Hospital Pharmacy Practice
`..... . .......... 2247
`Emergency Medicine Pharmacy Practice
`..... 2265
`Long-Term Care . . . . . . . . .
`. .............. 2272
`Aseptic Processing for Home Infusion Pharmaceuticals
`.2290
`The Pharmacist's Role in Substance Use Disorders . . ... 2303
`Complementary and Alternative Medical Health Care .. 2318
`Chronic Wound Care
`. . . . . . . . .
`. .. 2342
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 4
`
`

`

`I
`
`21 ST EDITION
`
`Remington
`
`The Science and Practice
`of Pharmacy
`
`\
`
`'~ LIPPINCOTT WILLIAMS & WILKINS
`
`A Wolters Kluwer Company
`Philadelphia• Baltimore· New York• London
`Buenos Aires • Hong Kong • Sydney • Tokyo
`
`•
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 5
`
`

`

`Ophthalmic Preparations
`
`John C Lang, PhD
`Robert E Roehrs, PhD
`Rajni Jani, PhD
`
`Cl-\1\PT E R 43
`
`INTRODUCTION 1
`Ophthalmic preparations are specialized dosage forms de(cid:173)
`signed to be instilled onto the external surface of the eye (topi(cid:173)
`cal), administered inside (intraocular) or adjacent (periocular
`such asjuxtascleral or subtenon) to the eye, or used in conjunc(cid:173)
`tion with an ophthalmic device. The latter include preparations
`used in conjunction with surgical implantation (such as an in(cid:173)
`traocular lens), dry eye formulations compatible with a punctal
`appliance such as a punctal plug, and extends to a variety of so(cid:173)
`lutions utilized in maintenance of contact lenses. The prepara(cid:173)
`tions may have any of several purposes, therapeutic, prophy(cid:173)
`lactic or palliative for topically administered agents, but
`includes mechanical, chemical and biochemical actions of
`agents used in the care of ocular appliances, and tissue pro(cid:173)
`phylaxis during or following surgery. Because of the dangers
`associated with their administration, or repetitive administra(cid:173)
`tion, intraocular and periocular preparations are restricted to
`therapeutic applications or surgical adjuncts.
`The versatility of dosage forms enables them to be suitable
`for the function of the preparation. Therapeutically active for(cid:173)
`mulations may be designed to provide extended action for ei(cid:173)
`ther convenience or reduction in risk of repetitive administra(cid:173)
`tion, improved bioavailability of the agent, or improved delivery
`to a targeted tissue. The residence of an ocular preparation may
`range from a few seconds needed for tears to clear an irritating
`substance, to hours for a gel, a gel-forming solution or anoint(cid:173)
`ment, to months or years for an intraocular or periocular
`dosage form. The preparation may be strictly therapeutic, or
`may be administered for its prophylaxis. The latter include sur(cid:173)
`gical adjunctives to maintain the health of fragile cells, post(cid:173)
`surgical or post-trauma preparations designed to prevent or re(cid:173)
`duce the likelihood of infection. Another form of prophylaxis,
`that for a device, is the antisoiling function provided by some
`contact lens solutions.
`Ophthalmic preparations are similar to parenteral dosage
`forms in their requirement for sterility as well as considera(cid:173)
`tions for osmotic pressure (tonicity), preservation, tissue com(cid:173)
`patibility, the avoidance of pyrogens in intraocular dosage
`forms, particulate matter and suitable packaging.
`Topical therapeutic dosage forms have customarily been re(cid:173)
`stricted to solutions, suspensions and ointments. But with ad(cid:173)
`vances in material science, the range of ophthalmic dosage
`forms has expanded significantly to include gels, either pre(cid:173)
`formed or spontaneous gels responsive to the ocular environ(cid:173)
`ment, and ocular inserts, both forms reducing dosage fre(cid:173)
`quency. These are most often multi-dose products containing
`suitable preservative(s) to meet compendia! preservative effec(cid:173)
`tiveness test (eg, USP, 2 Pharm. Europa,3 or JP") requirements.
`Now, however, single-dose units, also referred to as unit-dose
`products, that are preservative-free preparations generally
`
`850
`
`packaged in form-fill-seal plastic containers with 0.25 m L to up
`to 0.8 mL, have become availablf!. These unit dose containers
`are designed to be discarded after a single use or after a single
`day's use ifthe container has a reclosable feature and the prod(cid:173)
`uct is so labeled.
`Injections and implants have been developed for intraocular
`drug delivery. Irrigating solutions and viscoelastic gels are
`available specifically for adjunctive use in ophthalmic surgery.
`Specialized formulations are now available for use in the care
`of contact lenses. The designs of these preparations meeting all
`of the requirements for safety, efficacy, component compatibil(cid:173)
`ity, tissue acceptability, storage, shipping, and shelflife are be(cid:173)
`yond the scope of this review. Nonetheless, a description of the
`requirements and the designs for somf! of these formulations
`should be illustrative and didactic.
`From a historical perspective, preparations intended for
`treatment of eye disorders can be traced to the writings of the
`Egyptians, Greeks, and Romans. In the Middle Ages, collyria
`were referred to as materials that weni dissolved in water, milk
`or egg white and used as eyedrops. One such collyrium con(cid:173)
`tained the mydriatic substance belladonna to dilate the pupils
`of miladys' eyes for cosmetic purpose.
`From the time of belladonna collyria, ophthalmic technol(cid:173)
`ogy progressed at a pharmaceutical snail's pace until after
`World War II. Prior to WWII and into the 1950s, ophthalmic
`preparations were mostly compounded by the pharmacist for
`immediate use. Not until 1953 was there a legal requirement
`by FDA that all manufactured ophthalmic solutions be sterile.
`The range of medicinal agents to treat eye disorders was lim(cid:173)
`ited as was the state of eye surgery and vision correction,
`which was limited to eyeglasses. In the past fifty years, a
`modern pharmaceutical industry specializing in ophthalmic
`preparations has developed to support the advances in diag(cid:173)
`nosis and treatment of eye diseases, eye surgery and contact
`lenses. Because of the variety of ophthalmic products readily
`available commercially, the pharmacist now is rarely required
`to compound a patient's ophthalmic prescription. More impor(cid:173)
`tant, however, is for the pharmacist to appreciate even subtle
`differences in formulations that may impact efficacy, comfort,
`compatibility or suitability of a preparation for particular
`patients.
`Currently and in the future, in addition to the advances in
`dosage-form technology, drug molecules will be designed and
`optimized specifically for ophthalmic application. New thera(cid:173)
`pies may become available for preventing blindness caused by
`degenerative disease - including age-related macular degener(cid:173)
`ation (AMD), macular edema, and diabetic retinopathy.
`Biotechnological products may also become available to treat
`causes of multifactorial eye disorders like glaucoma. Such spe(cid:173)
`cialized therapeutic agents also will require carefully designed
`compatible dosage forms.
`
`Bee
`quire
`for the
`functic
`their p
`
`· ANA
`THE
`Inmru
`admin
`UnlikE
`with0t
`investi
`tricate
`ulus it
`signal
`sensiti
`the fw
`man ti
`Thes~
`43-3.
`\den ti
`These
`the ey1
`struct
`phasiz
`troduo
`theey
`
`Eye I
`Eyelic
`and C'
`
`BO
`ME
`
`STF
`
`DES
`ME
`
`END
`
`Figur
`The d1
`eyebal
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 6
`
`

`

`ER 43
`
`,
`
`125 mLto up
`e containers
`fter a single
`~d the prod-
`
`I
`intraocular
`tic gels are
`nic surgery.
`lin the care
`fleeting all
`com pa ti bi!-
`1 life are be-
`ption of the
`tmulations
`
`tended for
`ngs of the
`',s, collyria
`ater, milk
`iriurn con-
`he pupils
`
`c technol-
`ntil after
`hthalmic
`tiacist for
`uirement
`>e sterile.
`was lim-
`lrrection,
`years, a
`b.thalmic
`in diag-
`1 contact
`: readily
`required
`3 impor-
`n subtle
`:omfort,
`rticular
`
`mces in
`1ed and
`· thera-
`lSed by
`egener-
`1pathy.
`o treat
`ch spe-
`1signed ,
`
`Because dosage forms are fashioned to complement the re(cid:173)
`quirements of the therapeutic agent, and the latter are selected
`for their action upon particular tissues in order to modify their
`function, we will now turn to a description of ocular tissues and
`their physiology.
`
`ANATOMY AND PHYSIOLOGY OF
`THE EYE
`In many ways the human eye is an ideal organ for studying drug
`administration and disposition, organ physiology and function.
`Unlike many bodily organs, most of its structure can be inspected
`without surgical intervention. Its macroscopic responses can be
`investigated by direct observation. Its miraculous function so in(cid:173)
`tricate and complex - converting a physical electromagnetic stim(cid:173)
`ulus into a chemical signal that is coupled to distant neurons for
`signal processing by an electrochemical wave - can be detected by
`sensitive instruments attached to external tissues. The basis for
`the function and protection of this important organ that links
`man to his external environment are the tissues comprising it.
`ll'he structures to be described are illustrated in Figures 43-1 to
`~3-3. The first figure5 provides a horizontal section of the eyeball
`1dentifying the major structures and their interrelationships.
`The second figure6 shows in greater detail the anterior portion of
`the eye and eyelids, in vertical section, emphasizing some of the
`structures associated with tear apparatus. The third figure 6 em(cid:173)
`phasizes the flow of tears into the nasal structures. This brief in(cid:173)
`troduction will focus on the anatomical structures comprising
`the eye, and their function.
`
`Eyelids
`Eyelids serve two purposes: mechanical protection of the globe
`and creation of an optimum milieu for the cornea. The inner
`
`CHAPTER 43: OPHTHALMIC PREPARATIONS
`
`8 51
`
`surfaces of the eyelids and the outermost surfaces of the eye are
`lubricated by the tears, a composite of secretions from both
`lacrimal glands and specialized cells residing in both the bulbar
`(covering the sclera) and palpebral (covering the inner surface
`of the lids) conjunctiva. The antechamber has the shape of a
`narrow cleft directly over the front of the eyeball, with pocket(cid:173)
`like extensions upward and downward. The pockets are called
`the superior and inferior fornices (vaults), and the entire space,
`the cul-de-sac. The elliptical opening between the eyelids is
`called the palpebral fissure and the corner of the eyes where the
`eyelids meet are the canthi.
`
`Overview of Structure and Function of
`the Eyeball
`
`STRUCTURE
`The eyeball is housed in the bones of the skull, joined to form an
`approximately pyramid-shaped housing for the eyeball, called
`the orbit. The wall of the human eyeball (bulbus, globe) is com(cid:173)
`posed of three concentric layers that envelop the fluid and
`lenticular core. 7- 9
`Outer Fibrous Layer: The outer scleral layer is tough, pli(cid:173)
`able, but only slightly elastic. The anterior third is covered by
`the conjunctiva, a clear transparent mucous surface. The most
`anterior portion of the outer layer forms the cornea, a structure
`so regular and the water content so carefully adjusted that it
`acts as a clear, transparent window. It is devoid of blood ves(cid:173)
`sels. Over the remaining two-thirds of the globe the fibrous col(cid:173)
`lagen-rich coat is opaque (the white of the eye) and is called the
`sclera. It contains the microcirculation, which nourishes the tis(cid:173)
`sues of this anterior segment, and is usually white except when
`irritated vessels become dilated.
`The cornea, slightly thicker than the sclera and ranging in
`thickness from 500 microns to one millimeter, consists of five
`
`BOWMAN'S
`MEMBRANE
`
`ST ROMA
`L -
`DESCEMET'S
`MEMBRANE
`
`LATERAL RECTUS MUSCLE
`
`CENTRAL RETINAL
`VIEW
`
`TRABECULAR
`MESHWORK
`
`MEDIAL RECTUS MUSCLE
`
`Figure 43-1. A cutaway horizontal section of the eyeball illustrating the important anatomic structures and their interrelationships diagramatically.
`The different layers of the cornea are illustrated in the magnified view. Relative sizes are suggestive and not proportional. The diameter of a mature
`eyeball is generally slightly greater than one inch (courtesy, Alcon, Inc., Fort Worth, TX). See Color Plate 19.
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 7
`
`

`

`852
`
`PART 5: PHARMACEUTICAL MANUFACTURING
`
`WOLFRING'S
`GLANDS-".,._----~~ll
`
`GLANDS OF
`#---;r.,-:-+---MANZ
`
`CRYPTS OF
`HENLE•---l'!--~-:ffio~
`
`MEIBOMIAN
`GLANDS--ll'---mt'H
`
`TARSALPLATE-¥.----f~IC.ID
`
`VITREOUS
`HUMOR
`
`Figure 43-2. The front half of the eye, in vertical section, identifying the
`important structures associated with cornea and the front of the eye, in(cid:173)
`cluding the eyelids and the glands associated with tears.
`
`identifiable layers. Proceeding from the most anterior layer,
`these are the hydrophobic stratified squamous epithelium, which
`is underlaid by Bowman's membrane, then the stroma and De(cid:173)
`scemet's membrane, and then the innermost layer, the endothe(cid:173)
`lium. The stroma is a hydrophilic elastic network of highly orga(cid:173)
`nized connective tissue and is the thickest layer of the cornea. The
`fibrous collagen-rich Descemet's membrane separates the
`stroma from the single-squamous-cell layer of endothelium, the
`location of the pump that keeps the cornea in its relatively dehy(cid:173)
`drated transparent state. Functionally, the cornea serves as a bi(cid:173)
`layer barrier, the hydrophobic epithelium being the primary bar(cid:173)
`rier to hydrophilic molecules, and the hydrophilic stroma, the
`primary barrier to hydrophobic molecules. A schematic drawing
`of the cornea is provided in Figure 43-1.
`Middle Vascular Layer: The middle vascular layer, or uvea,
`provides nourishment to the eye and consists, moving from the
`back of the eye forward, of the choroid, the ciliary body, and the
`iris. The choroid consists of a pigmented vascular layer, colored
`by melanocytes and traversed by medium-sized arteries and
`veins, with the choriocapillaris containing a network of small
`vessels that nourish the neural retina. The ciliary body con(cid:173)
`tains muscles that control the extension of the lens allowing vi(cid:173)
`sual accommodation, as well as the ciliary processes that se(cid:173)
`crete aqueous humor into the posterior chamber to maintain
`the intraocular pressure that in turn keeps the eyeball fully ex(cid:173)
`panded. The pigmented iris is a ring of muscular tissue around
`the pupil, a round centric hole that acts as a variable aperture
`to control pupil diameter, and thereby the level of light enter(cid:173)
`ing the eye. The canal of Schlemm, one of the important paths
`for outflow of the aqueous humor, resides in the angle of the
`iris. Bruch's membrane separates the choroid from the retina.
`
`Neural Retina: This innermost layer of the eyeball is a complex
`tissue that supports the harvesting oflight through the action of
`photoreceptors - nerve cells specialized for distinguishing white
`from black (rods), or discerning color (cones). In addition, the
`retina consists of cells that support metabolism (like the heavily
`pigmented retinal pigmented epithelium, the RPE, which purges
`photoreceptors of spent molecules and metabolites, and regener·
`ates the cis-retinal), provide structure (astrocytes and Muelle
`cells), or contribute to the primary function of photodetection I sig·
`nal processing (the ganglion cells that begin to process the rl ·
`trochemical information transmitted from the photoreceptorsJ.
`Ocular Core: Within the globe, the crystalline lens spans the
`interior fluid-filled center close to the iris and is anchored by
`zonule fibers to the ciliary body. The lens is composed of a sin(cid:173)
`gle layer ofreplicating epithelial cells that with age flatten into
`layers oflong thin crystalline-filled lamellar fibers. The le.ns i•
`the only tissue in the body that retains all cells ever produced,
`a fact that contributes to age-related alterations in size, clarity
`and extensibility. A tough thin transparent membrane called
`the capsule covers the outermost layer of the lens.
`The aqueous and vitreous humors are interposed between
`the solid structures of the eye. The clear, fluid aqueous humor
`fills the globe anterior to the lens and is primarily responsible
`for maintaining correct intraocular pressure. The gel-like vitre(cid:173)
`ous humor accounts for most of the weight of the eye and re(cid:173)
`sides posterior to the lens in direct contact with the retina.
`
`FUNCTION
`
`The eyeball houses the optical apparatus that causes inverted
`reduced images of the outside world to form on the neural retina.
`Dimensional Stability: The optical function of the eye calls
`for stability of its dimensions, which is provided partly by the fi(cid:173)
`brous outer coat, but more effectively by the intraocular pres(cid:173)
`sure (IOP), which exceeds the pressure prevailing in the sur(cid:173)
`rounding tissues. This intraocular pressure is the result of a
`steady production of specific fluid, the aqueous humor, which
`
`NASAL
`SEPTUM
`
`Figure 43-3. The structures associated with the tears and lacrimal flo
`and access to the nasolacrimal system.
`
`originates fo
`leaves the ey
`resistance en
`ous producti(
`the intraocul
`function, the
`strates, and 1
`Optical Pc
`of the precor;
`pupil, the cr1
`The chief re~
`face of the cc
`that of air (J
`traversing tr
`humor to the
`is regulated
`fractive elem
`allows object
`commodatior
`of the ciliary
`image on the
`cause of the t
`cause of its g
`the pathway
`magnetic lig'
`chemical sigr
`processed by
`ported throu1
`conversion ol
`processable i
`retina, and i
`rapidly metal
`neural retina
`lying cell lay
`such as detac
`can result in
`Tissues Re
`or transparer
`clear image; t
`may interfere
`of the eye. Tr
`its organized
`sence of blood
`sels except at
`therefore, mu
`certain perme
`from the fluici
`from the air. '
`vessels is an ~
`Cloudines!
`excess pressu
`coma), the prl
`ciency of oxyg
`the wearing o
`cornea may h
`impairment o
`cornea.
`The cornei
`the cornea, bt
`have a very lt
`most sensitivl
`that the corn1
`supplying the
`The cornea
`bacterial inva
`abrasion (a t:
`pathogenic ba
`therefore, pla1
`eases of the c<
`ing abrasions
`cornea with so
`to infection.
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1013, Page 8
`
`

`

`lll is a complex
`~ the action of
`luishing white
`addition, the
`ke the heavily
`which purges
`and regener(cid:173)
`and Mueller
`tletection I sig(cid:173)
`cess the elec(cid:173)
`breceptorsJ.
`ens spans tne
`anchored by
`osed of a sin(cid:173)
`fe flatten into
`~s. The lenl'> is
`ver produced,
`n size, clarity
`brane called
`
`osed between
`lueous humor
`y responsible
`gel-like vitre(cid:173)
`e eye and re-
`e retina.
`
`ses inverted
`eural retina.
`the eye calls
`~rtly by the fi(cid:173)
`aocular pres(cid:173)
`g in the sur(cid:173)
`le result of a
`umor, which
`
`NASAL
`SEPTUM
`
`~
`
`~
`
`lacrimal flow
`
`originates from the ciliary processes anterior to the lens and
`leaves the eye by an intricate system of outflow channels. The
`resistance encountered during this passage and the rate of aque(cid:173)
`ous production are the principal factors determining the level of
`the intraocular pressure. In addition to this hydromechanical
`function, the aqueous humor acts as a carrier of nutrients, sub(cid:173)
`strates, and metabolites for the avascular tissues of the eye. 10
`Optical Pathway: The optical pathway consists, in sequence,
`of the precorneal tear film, the cornea, the aqueous humor, the
`pupil, the crystalline lens, the vitreous humor, and the retina.
`The chief refraction of light for the eye occurs at the outer sur(cid:173)
`face of the cornea where the index of refraction changes from
`that of air (LOO) to that of precorneal substance (1.38). After
`traversing the cornea, light passes through the clear aqueous
`humor to the pupil, where the amount oflight entering the eye
`is regulated by the pupillary diameter, and to the second re(cid:173)
`fractive element of the eye, the lens, whose variable focal length
`allows objects both near and far to be brought into focus (ac(cid:173)
`commodation). The shape of the lens, controlled by the muscles
`of the ciliary body, refracts and focuses the reduced inverted
`image on the retina. That image is sharp and clear, in part, be(cid:173)
`cause of the high transparency of the vitreous humor, which be(cid:173)
`cause of its gel-like state keeps debris and cells from entering
`the pathway for the light. The image formed by the electro(cid:173)
`magnetic light signal on the neural retina is converted to a
`chemical signal, changing cis- to trans- retinal, which in turn is
`processed by neural cells into an electrochemical signal trans(cid:173)
`ported through axons to central nerve bodies. This continuous
`conversion of the excitation associated with a retinal image to
`processable information, is integral to the functioning of the
`retina, and is the reason retinal tissue is amongst the most
`rapidly metabolizing tissues in the body. The dependence of the
`neural retina on the metabolic support provided by the under(cid:173)
`lying cell layer, the RPE, explains why damage to the tissue -
`such as detachment of the retina or diminished blood supply -
`can result in nearly immediate and permanent loss ofvision. 11
`Tissues Responsible for Refraction: Any alteration in the shape
`or transparency of the cornea interferes with the formation of a
`clear-i

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket